Peeples Cancer Institute at Hamilton Medical Center has expanded access to the latest in cancer research for patients in ...

Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials-Phase 2/3 ...

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

Discover Skye Bioscience's progress on nimacimab with early trial enrollment, extended treatment protocols, and robust regulatory plans.

Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States and a top ...

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will ...

Medera announced that the independent Data and Safety Monitoring Board has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical ...

Cargo Therapeutics, a Bay Area biotech company, announced in a filing Tuesday that it is discontinuing its drug development ...